Poletajew S Awomir, Majek Aleksandra, Magusiak Piotr, Ledzikowska Katarzyna, Dybowski Bartosz, Radziszewski Piotr
Department of Urology, Medical University of Warsaw, Warsaw, Poland..
Department of Urology, Medical University of Warsaw, Warsaw, Poland.
Urol J. 2017 Nov 4;14(6):5068-5070. doi: 10.22037/uj.v14i6.3781.
Intravesical BCG instillations improve recurrence free survival in patients with non-muscle-invasive bladder cancer (NMIBC).
This is a national survey study, covering 223 urological centres, aimed at reliable identification of BCG availability and implemented treatment patterns.
Response rate was 93.7%. BCG was used in 56.5% of urological departments. Another 22.7% referred patients to other hospitals for instillations, while 20.8% did not recommend BCG at all. The most common indications for BCG instillations were as follows: T1 tumours (88.5%), carcinoma in situ (83.6%) and high grade tumours (73.8%). Maintenance therapy was routinely abandoned in 16.4% of centres or was scheduled for <1 year, 1 year, 3 years and 1-3 years in 6.6%, 19.7%, 21.3% and 31.2% of centres, respectively. Continuation of BCGdespite treatment failure in carcinoma in situ cases was considered in 21.3% of departments.
Our findings indicate that BCG is underused, while patterns of maintenance and follow-up are suboptimal.
膀胱内灌注卡介苗可提高非肌层浸润性膀胱癌（NMIBC）患者的无复发生存率。
这是一项全国性调查研究，涵盖223个泌尿外科中心，旨在可靠地确定卡介苗的可获得性及实施的治疗模式。
应答率为93.7%。56.5%的泌尿外科科室使用卡介苗。另外22.7%的科室将患者转诊至其他医院进行灌注，而20.8%的科室根本不推荐使用卡介苗。卡介苗灌注最常见的适应证如下：T1期肿瘤（88.5%）、原位癌（83.6%）和高级别肿瘤（73.8%）。16.4%的中心常规放弃维持治疗，或分别在6.6%、19.7%、21.3%和31.2%的中心安排维持治疗时间小于1年、1年、3年以及1至3年。21.3%的科室考虑在原位癌病例治疗失败后继续使用卡介苗。
我们的研究结果表明，卡介苗未得到充分利用，而维持治疗和随访模式也不尽理想。
